Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies

Brodalumab, a human monoclonal IgG2‐antibody, acts as a potent antagonist at the interleukin‐17 receptor A, which is important in the pathogenesis of psoriasis. To characterize the pharmacokinetics of brodalumab and assess the effects of covariates, brodalumab concentrations from Phase 1a and Phase...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical pharmacology Vol. 54; no. 11; pp. 1230 - 1238
Main Authors:	Endres, Christopher J., Salinger, David H., Köck, Kathleen, Gastonguay, Marc R., Martin, David A., Klekotka, Paul, Nirula, Ajay, Gibbs, Megan A.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01-11-2014 American College of Clinical Pharmacology Wiley Subscription Services, Inc
Subjects:	Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use brodalumab Dermatologic Agents - administration & dosage Dermatologic Agents - pharmacokinetics Dermatologic Agents - therapeutic use Double-Blind Method Drug Administration Schedule Humans interleukin 17 receptor monoclonal antibody Population population pharmacokinetics Psoriasis Psoriasis - drug therapy monoclonal antibody psoriasis brodalumab interleukin 17 receptor population pharmacokinetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!